VJ Oncology

YouTube video interviews with Dr. Lucy Kennedy from Cleveland Clinic

• Development of AdAPT-001, a novel TGF-β-trap-enhanced oncolytic virus
• Phase I/II trial of AdAPT-001, an oncolytic virus, and a checkpoint inhibitor in solid tumors
• The future of AdAPT-001 in patients with solid tumors refractory to checkpoint inhibitors